• Home
  •  / Alexion Pharmaceuticals

Alexion Pharmaceuticals

OverviewSuggest Edit

Alexion is a global biopharmaceutical company focused on developing and delivering life-transforming therapies for patients with devastating and rare diseases. The company is engaged in the discovery, development and commercialization of biologic therapeutic products aimed at treating patients with severe and life-threatening disease states, including hematologic, kidney, and neurologic diseases, transplant rejection, cancer, and autoimmune disorders.
TypePublic
Founded1992
HQBoston, MA, USMap
Websitealexion.com
View Jobs (194)

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)3,082(+17%)
Job Openings194
Revenue (FY, 2020)$6.1 B(+22%)
Share Price (Jun 2021)$177.1
Cybersecurity ratingBMore

Key People/Management at Alexion Pharmaceuticals

Ludwig Hantson

Ludwig Hantson

CEO & Director
Tanisha Carino

Tanisha Carino

Executive Vice President, Chief Corporate Affairs Officer
John Orloff

John Orloff

Executive Vice President, Head of Research & Development
Indrani Franchini

Indrani Franchini

Executive Vice President, Chief Compliance Officer
Paul Clancy

Paul Clancy

Executive Vice President, Senior Advisor
Brian Goff

Brian Goff

Executive Vice President, Chief Commercial & Global Operations Officer
Show more

Alexion Pharmaceuticals Office Locations

Alexion Pharmaceuticals has offices in Boston, Washington, Frenchs Forest, Elsene and in 18 other locations
Boston, MA, US (HQ)
121 Seaport Blvd
Washington, DC, US
1455 Pennsylvania Ave NW #510
Frenchs Forest, AU
Suite 401, Level 4, Building A/20 Rodborough Rd
Elsene, BE
De Meeûssquare 37
São Paulo, BR
Av. Dr. Chucri Zaidan, 1240 - Chácara Santo Antônio (Zona Sul)
Vaughan, CA
300-3100 Rutherford Rd, Maple
Show all (23)

Alexion Pharmaceuticals Financials and Metrics

Alexion Pharmaceuticals Revenue

Embed Graph
View revenue for all periods
Alexion Pharmaceuticals's revenue was reported to be $6.07 b in FY, 2020
USD

Revenue (FY, 2020)

6.1b

Gross profit (FY, 2020)

5.5b

Gross profit margin (FY, 2020), %

90.9%

Net income (FY, 2020)

603.4m

EBIT (FY, 2020)

632.3m

Market capitalization (4-Jun-2021)

39.1b

Closing stock price (4-Jun-2021)

177.1

Cash (31-Dec-2020)

3.0b

EV

38.9b
Alexion Pharmaceuticals's current market capitalization is $39.1 b.
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

541.0m783.4m1.1b1.6b2.2b2.6b3.1b3.6b4.1b5.0b6.1b

Revenue growth, %

44%17%18%

Cost of goods sold

64.4m93.1m72.8m177.6m173.9m233.1m258.0m454.2m374.3m394.5m553.5m

Gross profit

476.5m690.3m1.1b1.4b2.1b2.4b2.8b3.1b3.8b4.6b5.5b
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

125.8m141.6m166.1m204.0m244.7m274.7m294.1m338.9m370.1m400.4m566.6m512.5m555.1m600.3m636.2m666.6m701.0m753.1m799.1m870.0m912.0m859.0m930.9m1.0b1.0b1.1b1.2b1.3b1.4b1.4b

Cost of goods sold

13.7m16.5m19.2m23.4m28.3m31.6m20.2m35.3m39.4m51.4m32.9m39.6m51.9m69.4m52.0m54.1m59.0m60.6m71.1m69.0m84.0m157.0m91.6m95.3m90.6m85.8m99.2m95.2m111.7m

Gross profit

112.1m125.1m146.9m180.7m216.5m243.1m273.9m303.7m330.7m349.0m533.7m472.9m503.3m530.9m584.2m612.6m642.1m692.5m728.0m801.0m828.0m702.0m839.3m949.7m935.9m1.1b1.1b1.2b1.3b

Gross profit Margin, %

89%88%88%89%88%88%93%90%89%87%94%92%91%88%92%92%92%92%91%92%91%82%90%91%91%92%92%92%92%
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

267.1m540.9m989.5m529.9m944.0m1.0b966.0m584.4m1.4b2.7b3.0b

Accounts Receivable

168.7m244.3m295.6m421.8m432.9m532.8m650.0m726.5m922.3m1.2b1.4b

Prepaid Expenses

26.9m50.8m75.3m87.3m189.4m217.6m292.9m426.4m456.1m

Inventories

62.2m81.4m94.5m102.6m176.4m289.9m375.0m460.4m472.5m627.6m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

212.1m210.0m289.4m347.9m438.2m359.4m806.2m905.5m1.0b936.5m910.4m528.3m612.0m752.2m916.8m1.3b1.2b710.2m597.6m762.0m713.0m542.0m550.0m511.8m727.5m1.2b1.5b2.0b2.2b2.4b2.9b2.3b

Accounts Receivable

127.0m154.1m200.7m212.7m221.3m267.4m282.7m311.4m323.9m355.3m405.0m429.0m440.7m436.5m479.9m535.8m512.3m586.2m609.3m676.8m660.0m710.0m705.0m776.7m853.7m910.2m1.0b1.1b1.1b1.3b1.4b1.4b

Prepaid Expenses

41.4m25.5m24.9m23.6m52.6m73.2m74.0m84.3m81.3m71.4m78.8m87.4m111.1m147.3m273.5m268.7m272.9m219.7m242.0m241.8m215.0m225.0m207.0m327.9m342.2m370.4m497.0m460.7m432.5m

Inventories

57.7m60.4m74.4m75.2m78.3m92.9m94.1m90.0m101.9m112.6m105.2m126.2m144.9m140.0m174.5m234.3m236.5m294.0m329.8m363.1m396.0m410.0m441.0m456.5m463.2m432.7m482.2m494.6m576.7m586.8m577.7m
show all
Annual
USDFY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

97.0m175.3m254.8m252.9m656.9m144.4m399.0m443.3m77.6m2.4b603.4m

Depreciation and Amortization

15.8m17.6m23.9m28.7m46.9m166.6m396.0m496.7m405.3m376.8m329.4m

Inventories

(14.1m)(12.2m)(6.3m)126.0k(66.8m)(88.4m)(84.0m)(88.2m)(14.7m)(156.9m)

Accounts Payable

47.5m79.8m61.7m136.6m264.6m(115.9m)150.0m(55.1m)230.7m122.5m
Quarterly
USDQ2, 2010Q3, 2010Q1, 2011Q2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

42.7m70.6m26.8m61.6m127.1m45.4m81.7m173.9m82.2m178.1m271.9m159.4m325.8m503.6m91.3m261.5m77.8m92.2m207.1m306.6m170.0m335.0m413.0m249.1m(208.3m)122.6m587.9m1.0b1.5b557.6m(510.5m)67.6m

Depreciation and Amortization

7.8m11.9m4.3m8.7m13.2m5.9m11.4m17.6m6.3m13.0m20.2m9.3m19.0m28.4m10.6m23.1m72.9m96.8m194.6m295.3m99.0m201.0m311.0m101.5m202.0m306.9m97.2m193.7m286.2m89.3m328.4m254.3m

Inventories

13.8m14.2m(10.4m)(9.5m)(10.9m)(9.7m)(9.3m)(3.5m)(5.5m)(14.4m)(5.0m)(20.9m)(35.0m)(26.2m)2.6m4.7m(7.4m)(3.8m)(39.0m)(72.2m)(19.0m)(33.0m)(69.0m)3.9m(4.1m)26.7m(11.2m)(105.9m)37.3m(15.1m)(10.3m)

Accounts Payable

6.4m24.9m5.4m36.9m54.5m(2.8m)76.9m59.9m(62.3m)(53.1m)4.0m(60.7m)78.3m166.5m(13.7m)(10.8m)(147.1m)(42.5m)(6.7m)92.8m39.0m61.0m102.0m(73.7m)(130.6m)(167.3m)23.6m207.1m(68.2m)(88.5m)23.7m
show all
USDQ2, 2010

Financial Leverage

1.1 x
Show all financial metrics

Alexion Pharmaceuticals Acquisitions / Subsidiaries

Company NameDateDeal Size
SyntimmuneSeptember 26, 2018$1.2 b

Alexion Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

86/100

Learn more about our premium products
SecurityScorecard logo

Alexion Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

Learn more about our premium products
CSRHub logo

Alexion Pharmaceuticals Online and Social Media Presence

Alexion Pharmaceuticals's Trends

Embed Graph

Alexion Pharmaceuticals News and Updates

May 25, 2021

: AstraZeneca’s $39 billion takeover of U.S.-based Alexion Pharmaceuticals examined by U.K. regulator

The deal has already been approved by the U.S. and Canadian authorities.
December 14, 2020

SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Alexion Pharmaceuticals, Inc. Buyout

WILMINGTON, Del., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Alexion Pharmaceuticals, Inc. (“Alexion”) (NASDAQ GS: ALXN) regarding possible breaches of fiduciary duties and other violations of law related to Alexion’s agreement to be acquired by…
December 06, 2019

Alexion Pharmaceuticals rejects Elliott push for "proactive sale"

Alexion Pharmaceuticals Inc said on Friday its board of directors had unanimously decided against hedge fund Elliott Management's push for a "proactive sale" process, saying it would not be in the best interest of shareholders.
October 16, 2019

Shareholder Alert: Ademi & O'Reilly, LLP Investigates whether Achillion Pharmaceuticals, Inc. has obtained a Fair Price in its sale to Alexion Pharmaceuticals, Inc.

MILWAUKEE, Oct. 16, 2019 /PRNewswire/ -- Ademi & O'Reilly, LLP is investigating Achillion (NASDAQ:ACHN) for possible breaches of fiduciary duty and other violations of the law in connection with the sale of Achillion to Alexion. Click here to learn how to join the action:...
October 16, 2019

Achillion Pharmaceuticals' stock rockets after Alexion Pharmaceuticals $930 million buyout deal

Shares of Achillion Pharmaceuticals Inc. rocketed 82% in premarket trading Wednesday, after the biopharmaceutical company agreed to be acquired by Alexion Pharmaceuticals Inc. in a cash deal valued at $930 million. Alexion's stock slipped 0.1% ahead of the open. Under terms of the deal, Alexion wi…
July 05, 2019

Stocks making the biggest moves premarket: Qualcomm, Rio Tinto, Alexion Pharmaceuticals & more

Names on the move ahead of the open.
Show more

Alexion Pharmaceuticals Blogs

February 20, 2020

Alexion to Present at the 9th Annual SVB Leerink Global Healthcare Conference

Dateline City: BOSTON BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that management will present at the SVB Leerink Global Healthcare Conference in New York, NY on Tuesday, February 25th, 2020 at 9:30 a.…
January 30, 2020

Alexion Reports Fourth Quarter and Full Year 2019 Results

Dateline City: BOSTON 4Q19 total revenues of $1,384.3 million, a 23 percent increase over 4Q18 4Q19 GAAP diluted EPS of $4.00; non-GAAP diluted EPS of $2.71 Received Japanese approval for SOL…
January 28, 2020

Alexion Completes Acquisition of Achillion

Dateline City: BOSTON – Acquisition adds two clinical-stage Factor D inhibitors to Alexion’s pipeline and provides promising development platform for additional complement-mediated diseases – …
January 24, 2020

UPDATED TIME: Alexion Fourth Quarter and Full Year 2019 Results Conference Call at 7:30am ET on Thursday, January 30, 2020

Dateline City: BOSTON BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that it has updated the time of its fourth quarter and full year 2019 earnings call on January 30, 2020 to 7:30 a.m. Eastern Ti…
January 17, 2020

Alexion to Report Fourth Quarter and Full Year 2019 Results on Thursday, January 30, 2020

Dateline City: BOSTON BOSTON--(BUSINESS WIRE)-- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the fourth quarter and full year ended December 31, 2019 before the US f…
January 14, 2020

Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS

Dateline City: BOSTON - 50-week global study to enroll ~350 patients across broad ALS population - BOSTON--(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today an…
Show more

 Alexion Pharmaceuticals Frequently Asked Questions

  • When was Alexion Pharmaceuticals founded?

    Alexion Pharmaceuticals was founded in 1992.

  • Who are Alexion Pharmaceuticals key executives?

    Alexion Pharmaceuticals's key executives are Ludwig Hantson, Tanisha Carino and John Orloff.

  • How many employees does Alexion Pharmaceuticals have?

    Alexion Pharmaceuticals has 3,082 employees.

  • What is Alexion Pharmaceuticals revenue?

    Latest Alexion Pharmaceuticals annual revenue is $6.1 b.

  • What is Alexion Pharmaceuticals revenue per employee?

    Latest Alexion Pharmaceuticals revenue per employee is $2 m.

  • Who are Alexion Pharmaceuticals competitors?

    Competitors of Alexion Pharmaceuticals include Regeneron Pharmaceuticals, Epirium Bio and United Neuroscience.

  • Where is Alexion Pharmaceuticals headquarters?

    Alexion Pharmaceuticals headquarters is located at 121 Seaport Blvd, Boston.

  • Where are Alexion Pharmaceuticals offices?

    Alexion Pharmaceuticals has offices in Boston, Washington, Frenchs Forest, Elsene and in 18 other locations.

  • How many offices does Alexion Pharmaceuticals have?

    Alexion Pharmaceuticals has 23 offices.